Why Women’s Health Diagnostics Requires More Than Capital

We are currently closing our pre seed round to complete the technical and clinical preparation phase for YON E’s phase 1 clinical trials.

For us, this round is about reaching the next level of responsibility.

We have validated sensor performance in laboratory settings. Now we are entering the phase where regulatory preparation, clinical validation, manufacturing readiness, usability testing, backend development, and AI-supported software must come together. That requires capital. More importantly, it requires the right kind of capital.

Women’s health diagnostics cannot be built like standard consumer technology. A woman will not trust a device with intimate health data only because the product looks good. A clinician will not use a new diagnostic tool only because the market opportunity is attractive. Regulators need evidence, structure, and safety. The foundation needs to be strong from the beginning. 

YON E is being developed to measure biomarkers directly at the source and translate those signals into usable insight. That matters because women’s biology does not move in isolated moments. Cycle patterns, vaginal health, fertility signals, infections, hormonal changes, and microbiome-related shifts evolve over time. Yet most women still receive answers too late.

The investment will fund our next critical milestones: prototype completion, biocompatibility and usability validation, preparation for clinical trials, and further development of our backend and AI-supported software environment.

The biggest milestone now is the completion of YON E prototype. For us, that means integrating the sensor into the product housing and usability environment. It connects what we have validated in the lab with the real product experience women will eventually use.

That step prepares us for initiating clinical trials and for regulatory documentation readiness.

In women’s health diagnostics, defensibility does not come from branding alone. It comes from validation, data, regulatory progress, clinical relationships, and user trust. Those assets take time to build. They are also difficult to copy.

This is the reason why we prefer  investors who understand regulated healthcare innovation.

Capital matters, but capital alone is not enough. The right partner brings patience, strategic thinking, and access to clinical, regulatory, or healthcare distribution networks.

YON E sits at the intersection of medical technology, diagnostics, women’s health, data, and AI-supported insight. The opportunity is significant, but the responsibility is even bigger.

We are dealing with intimate health information. Fertility. Vaginal health. Cycle patterns. Early biological signals are still too often missed or misunderstood. The future of women’s health cannot be built on assumptions alone.

It needs to be measured. It needs to be evidence-based. And above all, it needs to be built on trust.

If you are a clinician, researcher, healthcare partner, or investor working in women’s health, we would love to hear from you. The next phase of YON E is about building clinical evidence and trust around the data women have needed for far too long.

Roswitha Verwer 

Founder & CEO YON E